Eculizumab Reduces Relapse Risk in Neuromyelitis Optica Spectrum Disorder
The terminal complement inhibitor eculizumab reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD).
Neuromyelitis Optica
Increased Pain Medication Use in Patients With Relapse of Neuromyelitis Optica Spectrum Disorder
Patients with neuromyelitis optica spectrum disorder who experience relapses use more pain medication than non-relapsing patients.
Enspryng, a Self-Administered Treatment for NMOSD, Gets FDA Approval
The FDA has approved Enspryng (satralizumab-mwge; Genentech) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Patients With Neuromyelitis Optica at Increased Risk for Fracture
Given the limited data is available on bone health of patients with NMOSD-AQP4, researchers aimed to investigate their risk for fracture and bone loss.
Satralizumab Can Delay and Reduce Neuromyelitis Optica Spectrum Disorder Relapse Rate
Satralizumab monotherapy may reduce the risk for neuromyelitis optics spectrum disorder relapse, and has a favorable safety profile.
COVID-19 and Neuromyelitis Optica Disorder: A Need for Guidance-Based Management
Little guidance has been issued on how to manage patients with COVID-19 and coexisting neurological disorders.
Inebilizumab Shows Promise in Neuromyelitis Optica Spectrum Disorder
Inebilizumab is superior to placebo in reducing the risk for a neuromyelitis optica spectrum disorder attack.
FDA to Review Satralizumab for Neuromyelitis Optica Spectrum Disorder
The FDA has accepted the Biologics License Application (BLA) for satralizumab (Genentech) for the treatment of neuromyelitis optica spectrum disorder.
Immunosuppressive Therapy Prior to Pregnancy Not Associated With Negative Long-Term Outcomes in NMOSD
The use of immunosuppressive therapy (IST) prior to pregnancy in women with neuromyelitis optica spectrum disorder (NMOSD) is not associated with negative long-term outcomes.
FDA to Review Inebilizumab for Neuromyelitis Optica Spectrum Disorder
The Food and Drug Administration has accepted for review the Biologics License Application for inebilizumab for the treatment of patients with neuromyelitis optica spectrum disorder.
-
Loading...
-
Loading...
Next post in General Neurology
